SCHEMBL1498129

SCHEMBL1498129

[NH]C(=O)c1ccc(C(=O)O)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.71
TP53 P04637 1/20 0.71
SRD5A2 P31213 6/20 0.60
CA1 P00915 2/20 0.57
CA2 P00918 2/20 0.57
CA12 O43570 1/20 0.57
CA3 P07451 1/20 0.57
TYR P14679 1/20 0.57
DRD1 P21728 1/20 0.57
CA4 P22748 1/20 0.57
CA6 P23280 1/20 0.57
CA5A P35218 1/20 0.57
CA7 P43166 1/20 0.57
CA9 Q16790 1/20 0.57
CA14 Q9ULX7 1/20 0.57
CA5B Q9Y2D0 1/20 0.57
DAO P14920 1/20 0.55
NAPRT Q6XQN6 1/20 0.55
ALDH1A1 P00352 2/20 0.55
ALOX15 P16050 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Terephthalic Acid SCHEMBL2511919 0.84 TSHR (1.00) TSHRTP53SRD5A2CA1CA2
Terephthalic Acid SCHEMBL175823 0.84 TSHR (1.00) TSHRTP53SRD5A2CA1CA2
Terephthalic Acid SCHEMBL5053781 0.84 TSHR (1.00) TSHRTP53SRD5A2CA1CA2
Terephthalic Acid SCHEMBL1655 0.84 TSHR (1.00) TSHRTP53SRD5A2CA1CA2
Terephthalic Acid SCHEMBL28312118 0.81 TSHR (0.80) TSHRTP53SRD5A2CA1CA2
Terephthalic Acid SCHEMBL25381766 0.81 TSHR (0.92) TSHRTP53SRD5A2CA1CA2
Terephthalic Acid SCHEMBL996091 0.81 TSHR (0.92) TSHRTP53SRD5A2CA1CA2
Terephthalic Acid SCHEMBL6664065 0.81 TSHR (0.92) TSHRTP53SRD5A2CA1CA2
Terephthalic Acid SCHEMBL21443891 0.81 TSHR (0.92) TSHRTP53SRD5A2CA1CA2
Terephthalic Acid SCHEMBL20704876 0.81 TSHR (0.92) TSHRTP53SRD5A2CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9198426-B2 Use of 5 pyridin-4-yl-1,3-thiazoles for controlling phytopathogenic fungi BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-12-01 US claimed
EP-2378880-A1 USE OF 5-PYRIDIN-4YL(1,3)THIAZOLE FOR TREATING PHYTOPATHOGENIC FUNGI BAYER CROPSCIENCE AG (DE) 2011-10-26 EP claimed
US-20100168185-A1 Use of 5-pyridin-4-yl-1,3-thiazoles for controlling phytopathogenic fungi BAYER CORPSCIENCE AG (DE) 2010-07-01 US claimed
WO-2010069494-A1 USE OF 5-PYRIDIN-4YL(1,3)THIAZOLE FOR TREATING PHYTOPATHOGENIC FUNGI BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2010-06-24 WO claimed
EP-2198710-A1 Use of 5-pyridin-4yl-(1,3) thiazoles for combating phytopathogenic fungi Bayer CropScience AG (DE) 2010-06-23 EP claimed
US-5932551-A INHIBITORS OF MATRIX METALLOENDOPROTEINASE-MEDIATED DISEASES MERCK & CO., INC. (US) 1999-08-03 US claimed
EP-0586537-A4 SUBSTITUTED N-CARBOXYALKYLPEPTIDYL DERIVATIVES AS ANTIDEGENERATIVE ACTIVE AGENTS MERCK & CO INC (US) 1997-06-25 EP claimed
EP-0604800-A1 4- 4- 4-(carboxyalkyl)-phenyl amino carbonyl -phenyl -piperedines as aggregation inhibitors Dr. Karl Thomae GmbH (DE) 1994-07-06 EP claimed
EP-0586537-A1 SUBSTITUTED N-CARBOXYALKYLPEPTIDYL DERIVATIVES AS ANTIDEGENERATIVE ACTIVE AGENTS MERCK & CO. INC. (US) 1994-03-16 EP claimed
WO-1992021360-A1 SUBSTITUTED N-CARBOXYALKYLPEPTIDYL DERIVATIVES AS ANTIDEGENERATIVE ACTIVE AGENTS MERCK & CO., INC. (US) 1992-12-10 WO claimed
US-4008211-A Betainic azo dyestuffs containing cobalt in complex union with a colorless, tridentate ligand CIBA-GEIGY AG (CH) 1977-02-15 US claimed
US-20230348522-A1 METHOD FOR PRODUCING BICYCLIC PHOSPHORAMIDITE DAIICHI SANKYO COMPANY, LIMITED (JP) 2023-11-02 US disclosed
WO-2021075538-A1 METHOD FOR PRODUCING BICYCLIC PHOSPHORAMIDITE 第一三共株式会社 2021-04-22 WO disclosed
US-10190009-B2 Ink composition, ink jet recording method using same, and colored material NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2019-01-29 US disclosed
US-20160160065-A1 INK COMPOSITION, INK JET RECORDING METHOD USING SAME, AND COLORED MATERIAL NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2016-06-09 US disclosed
US-4997848-A Enzyme inhibitors SANKYO COMPANY, LIMITED (JP) 1991-03-05 US disclosed
US-4923869-A INOTROPIC, VASODILATING, AND ANTITHROMBOTIC AGENTS MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1990-05-08 US disclosed
EP-0314435-A2 Octahydronaphthalene oxime derivatives for cholesterol synthesis inhibition, processes for their preparation and compositions containing them Sankyo Company Limited (JP) 1989-05-03 EP disclosed
EP-0193013-B1 BENZIMIDAZOLYL-PYRIDAZINONES MERCK PATENT GmbH (DE) 1989-04-19 EP disclosed
EP-0193013-A2 Benzimidazolyl-pyridazinones MERCK PATENT GmbH (DE) 1986-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168185-A1 Use of 5-pyridin-4-yl-1,3-thiazoles for controlling phytopathogenic fungi PIR, PNPO, PDXK TSHR 4142/4885TP53 4260/4885SRD5A2 2711/4885
US-20230348522-A1 METHOD FOR PRODUCING BICYCLIC PHOSPHORAMIDITE PFAS, ENPP1, NAAA TSHR 4509/4885TP53 2715/4885SRD5A2 3607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.